SK19442000A3 - Tlakov inhaltory s meranmi dvkami a farmaceutick aeroslov formulcie - Google Patents

Tlakov inhaltory s meranmi dvkami a farmaceutick aeroslov formulcie Download PDF

Info

Publication number: SK19442000A3
Authority: SK; Slovakia
Prior art keywords: aerosol formulation; weight; amount; metered dose; dose inhaler
Prior art date: 1998-06-19

Application number

SK1944-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Frank E. Blondino

Michael Brucato

Maria W. Buenafe

Original Assignee

Baker Norton Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1999-06-18

Publication date

2001-09-11

1999-06-18 Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.

2001-09-11 Publication of SK19442000A3 publication Critical patent/SK19442000A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 144
238000009472 formulation Methods 0.000 title claims abstract description 133
229940125388 beta agonist Drugs 0.000 title claims abstract description 45
239000008249 pharmaceutical aerosol Substances 0.000 title 1
239000000443 aerosol Substances 0.000 claims abstract description 131
239000003814 drug Substances 0.000 claims abstract description 70
229940079593 drug Drugs 0.000 claims abstract description 69
229940071648 metered dose inhaler Drugs 0.000 claims description 44
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 36
229960002848 formoterol Drugs 0.000 claims description 36
239000002904 solvent Substances 0.000 claims description 35
239000004094 surface-active agent Substances 0.000 claims description 31
239000000725 suspension Substances 0.000 claims description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims description 25
239000003795 chemical substances by application Substances 0.000 claims description 25
229960000193 formoterol fumarate Drugs 0.000 claims description 25
239000002245 particle Substances 0.000 claims description 21
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 18
230000003381 solubilizing effect Effects 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 4
150000001298 alcohols Chemical class 0.000 claims description 4
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
150000002170 ethers Chemical class 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
-1 polyoxyethylene Polymers 0.000 claims description 4
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 3
150000005846 sugar alcohols Polymers 0.000 claims description 3
238000002664 inhalation therapy Methods 0.000 abstract description 2
239000000463 material Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 12
WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 11
239000010419 fine particle Substances 0.000 description 8
238000000034 method Methods 0.000 description 7
238000003860 storage Methods 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
238000001816 cooling Methods 0.000 description 4
239000006184 cosolvent Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
239000002253 acid Substances 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
238000002144 chemical decomposition reaction Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical class CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
235000019407 octafluorocyclobutane Nutrition 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 1
229960004692 perflenapent Drugs 0.000 description 1
KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
229950003332 perflubutane Drugs 0.000 description 1
NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
229960004065 perflutren Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000003566 sealing material Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Dispersion Chemistry (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1944-2000A 1998-06-19 1999-06-18 Tlakov inhaltory s meranmi dvkami a farmaceutick aeroslov formulcie SK19442000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/099,779 US6451285B2 (en)	1998-06-19	1998-06-19	Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
PCT/US1999/013863 WO1999065460A2 (en)	1998-06-19	1999-06-18	Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist

Publications (1)

Publication Number	Publication Date
SK19442000A3 true SK19442000A3 (sk)	2001-09-11

Family

ID=22276581

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1944-2000A SK19442000A3 (sk)	1998-06-19	1999-06-18	Tlakov inhaltory s meranmi dvkami a farmaceutick aeroslov formulcie

Country Status (23)

Country	Link
US (2)	US6451285B2 (de)
EP (2)	EP1306082B1 (de)
JP (1)	JP2002518100A (de)
KR (1)	KR20010053025A (de)
CN (2)	CN1154477C (de)
AR (1)	AR018891A1 (de)
AT (2)	ATE250409T1 (de)
AU (1)	AU762927B2 (de)
BR (1)	BR9912170A (de)
CA (1)	CA2335303A1 (de)
CO (1)	CO5031245A1 (de)
DE (2)	DE69911602T2 (de)
DK (2)	DK1085856T3 (de)
ES (2)	ES2205848T3 (de)
HU (1)	HUP0102468A3 (de)
IL (1)	IL140340A0 (de)
NO (1)	NO20006466L (de)
PL (1)	PL345399A1 (de)
PT (2)	PT1306082E (de)
RU (1)	RU2214230C2 (de)
SK (1)	SK19442000A3 (de)
WO (1)	WO1999065460A2 (de)
ZA (1)	ZA200007455B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9616237D0 (en)	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
US6451285B2 (en) *	1998-06-19	2002-09-17	Baker Norton Pharmaceuticals, Inc.	Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr)	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
US6315985B1 (en) *	1999-06-18	2001-11-13	3M Innovative Properties Company	C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it)	1999-07-23	2002-09-09	Chiesi Farma Spa	Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) *	2000-01-07	2003-07-15	Chiesi Farma Spa	Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) *	2000-02-22	2003-07-15	Chiesi Farma Spa	Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en)	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
EE05167B1 (et)	2000-05-22	2009-06-15	Chiesi Farmaceutici S.P.A.	Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
US20030072717A1 (en) *	2001-02-23	2003-04-17	Vapotronics, Inc.	Inhalation device having an optimized air flow path
CN100496608C (zh) *	2001-03-30	2009-06-10	洁垢技术有限公司	药用气溶胶制剂
ES2222294T3 (es) *	2001-07-02	2005-02-01	Chiesi Farmaceutici S.P.A.	Formulacion optimizada de tobramicina para administracion en forma de aerosol.
US20030178022A1 (en) *	2001-12-21	2003-09-25	Chiesi Farmaceutici S.P.A.	Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
DE10205087A1 (de) *	2002-02-07	2003-08-21	Pharmatech Gmbh	Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
ME00077B (me) *	2002-03-01	2010-06-10	Chiesi Farm Spa	Formoterol najfiniji preparat
GB0207899D0 (en) *	2002-04-05	2002-05-15	3M Innovative Properties Co	Formoterol and cielesonide aerosol formulations
US20050158248A1 (en) *	2002-08-21	2005-07-21	Xian-Ming Zeng	Method of preparing dry powder inhalation compositions
GB0219511D0 (en) *	2002-08-21	2002-10-02	Norton Healthcare Ltd	Method of preparing dry powder inhalation compositions
US8273331B2 (en) *	2002-08-21	2012-09-25	Norton Healthcare Ltd.	Inhalation compositions
US6979580B2 (en)	2002-12-09	2005-12-27	Progressant Technologies, Inc.	Process for controlling performance characteristics of a negative differential resistance (NDR) device
GB0323684D0 (en)	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0323685D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
EP1595531A1 (de)	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2007008427A2 (en) *	2005-07-08	2007-01-18	Xemplar Pharmaceuticals, Llc	Aerosol compositions and methods
US8367734B1 (en)	2005-08-11	2013-02-05	Amphastar Pharmaceuticals Inc.	Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
PT2435025T (pt) *	2009-05-29	2016-11-11	Pearl Therapeutics Inc	Administração, por via respiratória, de agentes activos
GB0918149D0 (en)	2009-10-16	2009-12-02	Jagotec Ag	Improved medicinal aerosol formulation
US20120272951A1 (en)	2009-12-16	2012-11-01	3M Innovative Properties Company	Formulations and methods for controlling mdi particle size delivery
GB201108039D0 (en)	2011-05-13	2011-06-29	Mexichem Amanco Holding Sa	Compositions
GB201117621D0 (en)	2011-10-12	2011-11-23	Mexichem Amanco Holding Sa	Compositions
GB201117619D0 (en)	2011-10-12	2011-11-23	Mexichem Amanco Holding Sa	Compositions
JP6454323B2 (ja)	2013-03-15	2019-01-16	パールセラピューティクス，インコーポレイテッド	粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201306984D0 (en)	2013-04-17	2013-05-29	Mexichem Amanco Holding Sa	Composition
CN112472689B (zh)	2015-12-04	2023-01-17	墨西哥氟石股份公司	药物组合物
EP3515425B1 (de)	2016-09-19	2021-06-09	Mexichem Fluor S.A. de C.V.	Pharmazeutische zusammensetzung enthaltend salmeterol
JP6781829B2 (ja)	2016-09-19	2020-11-04	メキシケムフローエセ・ア・デ・セ・ヴェ	医薬組成物
CN113288869A (zh)	2016-09-19	2021-08-24	墨西哥氟石股份公司	药物组合物
CN109464429B (zh) *	2018-12-13	2021-04-27	上海方予健康医药科技有限公司	一种吸入压力定量气雾剂药物组合物及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE556587A (de)	1957-01-31	1957-04-11
BE786200A (fr) *	1971-07-13	1973-01-12	Boehringer Sohn Ingelheim	Traitement par inhalation de maladies bronchiques
NL7708731A (nl)	1976-08-13	1978-02-15	Montedison Spa	Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1178889A (en) *	1980-08-28	1984-12-04	Kenneth S. Su	Intranasal formulation
US5225183A (en) *	1988-12-06	1993-07-06	Riker Laboratories, Inc.	Medicinal aerosol formulations
US5766573A (en) *	1988-12-06	1998-06-16	Riker Laboratories, Inc.	Medicinal aerosol formulations
IL97065A (en)	1990-02-02	1994-01-25	Fisons Plc	Repellent preparations for aerosol
RU2098082C1 (ru) *	1990-06-28	1997-12-10	Глэксо Инк.	Аэрозольная лекарственная композиция для ингаляций (варианты)
JP2854974B2 (ja)	1990-06-29	1999-02-10	フアイソンズ・ピーエルシー	加圧エアロゾル組成物
ATE114112T1 (de)	1990-10-18	1994-12-15	Minnesota Mining & Mfg	Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
MX9203481A (es)	1990-10-18	1992-07-01	Minnesota Mining & Mfg	Formulaciones.
US5190029A (en)	1991-02-14	1993-03-02	Virginia Commonwealth University	Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en)	1991-03-14	1993-04-21	Ciba-Geigy Ag	Pharmaceutical aerosol formulations
WO1992022286A1 (en)	1991-06-12	1992-12-23	Minnesota Mining And Manufacturing Company	Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de)	1991-07-17	1993-01-21	Schwabe Willmar Gmbh & Co	Aerosol-zubereitung und verwendung eines treibmittels dafuer
IL103238A (en) *	1991-09-25	1995-07-31	Fisons Plc	Pressurised aerosol compositions
US5736124A (en) *	1991-12-12	1998-04-07	Glaxo Group Limited	Aerosol formulations containing P134a and particulate medicament
NZ246046A (en) *	1991-12-12	1995-12-21	Glaxo Group Ltd	Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
DK0717987T3 (da)	1991-12-18	2001-11-12	Minnesota Mining & Mfg	Suspension-aerosol-formuleringer
CA2123909C (en)	1991-12-18	2002-10-01	Christer Carl Gustav Carling	New combination of formoterol and budesonide
DE59206234D1 (de)	1991-12-31	1996-06-13	Hoechst Ag	Medizinische Aerosolformulierung
US5833950A (en) *	1992-07-31	1998-11-10	Glaxo Group Limited	Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
ES2129117T3 (es) *	1992-12-09	1999-06-01	Boehringer Ingelheim Pharma	Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
US5492688A (en)	1993-04-28	1996-02-20	The Center For Innovative Technology	Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5508023A (en)	1994-04-11	1996-04-16	The Center For Innovative Technology	Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
JP4155594B2 (ja)	1994-12-22	2008-09-24	アストラゼネカ・アクチエボラーグ	エアゾール製剤
DE4446891A1 (de) *	1994-12-27	1996-07-04	Falk Pharma Gmbh	Stabile wäßrige Budesonid-Lösung
GB9612297D0 (en)	1996-06-11	1996-08-14	Minnesota Mining & Mfg	Medicinal aerosol formulations
GB9616237D0 (en) *	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
US6039932A (en) *	1996-09-27	2000-03-21	3M Innovative Properties Company	Medicinal inhalation aerosol formulations containing budesonide
SE9603669D0 (sv)	1996-10-08	1996-10-08	Astra Ab	New combination
WO1998024420A1 (en)	1996-12-04	1998-06-11	Bioglan Ireland (R & D) Limited	Pharmaceutical compositions and devices for their administration
US6451285B2 (en) *	1998-06-19	2002-09-17	Baker Norton Pharmaceuticals, Inc.	Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) *	1998-12-18	1999-12-21	Baker Norton Pharmaceuticals, Inc.	Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

1998
- 1998-06-19 US US09/099,779 patent/US6451285B2/en not_active Expired - Fee Related
1999
- 1999-06-18 DK DK99931837T patent/DK1085856T3/da active
- 1999-06-18 ES ES99931837T patent/ES2205848T3/es not_active Expired - Lifetime
- 1999-06-18 PL PL99345399A patent/PL345399A1/xx unknown
- 1999-06-18 DK DK02026980T patent/DK1306082T3/da active
- 1999-06-18 AT AT99931837T patent/ATE250409T1/de not_active IP Right Cessation
- 1999-06-18 JP JP2000554340A patent/JP2002518100A/ja active Pending
- 1999-06-18 DE DE69911602T patent/DE69911602T2/de not_active Expired - Fee Related
- 1999-06-18 KR KR1020007014438A patent/KR20010053025A/ko not_active Ceased
- 1999-06-18 AU AU48259/99A patent/AU762927B2/en not_active Ceased
- 1999-06-18 PT PT02026980T patent/PT1306082E/pt unknown
- 1999-06-18 CN CNB998088641A patent/CN1154477C/zh not_active Expired - Fee Related
- 1999-06-18 PT PT99931837T patent/PT1085856E/pt unknown
- 1999-06-18 WO PCT/US1999/013863 patent/WO1999065460A2/en not_active Ceased
- 1999-06-18 RU RU2001101889/14A patent/RU2214230C2/ru not_active IP Right Cessation
- 1999-06-18 HU HU0102468A patent/HUP0102468A3/hu unknown
- 1999-06-18 EP EP02026980A patent/EP1306082B1/de not_active Expired - Lifetime
- 1999-06-18 EP EP99931837A patent/EP1085856B1/de not_active Expired - Lifetime
- 1999-06-18 AT AT02026980T patent/ATE260093T1/de not_active IP Right Cessation
- 1999-06-18 CN CNA2003101046076A patent/CN1522692A/zh active Pending
- 1999-06-18 ES ES02026980T patent/ES2215153T3/es not_active Expired - Lifetime
- 1999-06-18 BR BR9912170-0A patent/BR9912170A/pt not_active IP Right Cessation
- 1999-06-18 CA CA002335303A patent/CA2335303A1/en not_active Abandoned
- 1999-06-18 IL IL14034099A patent/IL140340A0/xx unknown
- 1999-06-18 DE DE69915144T patent/DE69915144T2/de not_active Expired - Fee Related
- 1999-06-18 AR ARP990102934A patent/AR018891A1/es not_active Application Discontinuation
- 1999-06-18 SK SK1944-2000A patent/SK19442000A3/sk unknown
- 1999-06-21 CO CO99038537A patent/CO5031245A1/es unknown
2000
- 2000-12-13 ZA ZA200007455A patent/ZA200007455B/en unknown
- 2000-12-18 NO NO20006466A patent/NO20006466L/no not_active Application Discontinuation
2002
- 2002-07-02 US US10/190,094 patent/US20030077230A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1085856B1 (de)	2003-09-24
EP1085856A2 (de)	2001-03-28
DE69915144D1 (de)	2004-04-01
AR018891A1 (es)	2001-12-12
CN1154477C (zh)	2004-06-23
BR9912170A (pt)	2001-10-23
US20020018753A1 (en)	2002-02-14
ZA200007455B (en)	2002-06-13
ES2205848T3 (es)	2004-05-01
AU762927B2 (en)	2003-07-10
US6451285B2 (en)	2002-09-17
DE69911602T2 (de)	2004-07-01
PL345399A1 (en)	2001-12-17
CN1522692A (zh)	2004-08-25
ES2215153T3 (es)	2004-10-01
HUP0102468A2 (hu)	2002-03-28
EP1306082B1 (de)	2004-02-25
US20030077230A1 (en)	2003-04-24
KR20010053025A (ko)	2001-06-25
PT1085856E (pt)	2004-01-30
ATE260093T1 (de)	2004-03-15
NO20006466L (no)	2001-02-16
WO1999065460A2 (en)	1999-12-23
WO1999065460A3 (en)	2000-04-27
NO20006466D0 (no)	2000-12-18
ATE250409T1 (de)	2003-10-15
CO5031245A1 (es)	2001-04-27
IL140340A0 (en)	2002-02-10
HUP0102468A3 (en)	2002-12-28
RU2214230C2 (ru)	2003-10-20
JP2002518100A (ja)	2002-06-25
CN1310611A (zh)	2001-08-29
AU4825999A (en)	2000-01-05
CA2335303A1 (en)	1999-12-23
DE69911602D1 (de)	2003-10-30
DK1306082T3 (da)	2004-06-01
EP1306082A1 (de)	2003-05-02
DK1085856T3 (da)	2003-12-08
DE69915144T2 (de)	2004-12-09
PT1306082E (pt)	2004-05-31

Publication	Publication Date	Title
US6451285B2 (en)	2002-09-17	Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en)	1999-12-21	Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
CA2352484C (en)	2010-05-04	Pressurised metered dose inhalers (mdi)
BG107256A (bg)	2003-06-30	Стабилен фармацевтичен разтвор за инхалатори с отмервана доза под налягане
US6290930B1 (en)	2001-09-18	Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
SK16062002A3 (sk)	2003-04-01	Farmaceutický prostriedok na použitie v aerosólovom inhalátore s odmeranou dávkou a spôsob jeho výroby
Murata et al.	2012	Effect of the moisture content in aerosol on the spray performance of Stmerin® D hydrofluoroalkane preparations (2)
CZ20004793A3 (cs)	2001-05-16	Tlakové inhalátory s odměřenými dávkami a farmaceutické aerosolové přípravky
AU2003235032A1 (en)	2003-09-11	Pressurized metered dose inhalers and pharmaceutical aerosol formulations
MXPA00012655A (en)	2001-12-13	Pressurized metered dose inhalers and pharmaceutical aerosol formulations
MXPA01006082A (en)	2002-06-05	Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol
MXPA01006083A (en)	2002-06-05	Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide